Cardiol Therapeutics Inc.
CRDLHealthcare|Drug Manufacturers - Specialty & Generic|CA
$0.99
+0.07 (+7.39%)
DCF Value
$0.15
Tangible Book / Share
$0.21
Cash / Share
$0.23
About
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
Stock Price
-2.5%(1Y)
1M
-23.5%
3M
-29.9%
6M
-24.6%
YTD
+4.3%
1Y
-5.2%
3Y
+20.1%
5Y
-61.0%
Pipeline Summary
4 total trials0
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
Completed: 2Terminated: 1Recruiting: 1
Active Trials (1)
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
NCT06708299Recurrent Pericarditis
Phase 3Recruiting
Enrollment: 110 participants
Key Facts
Market Cap$120.1M
Employees0
CEODavid G. Elsley
IPO DateJan 15, 2019
Beta0.52
52-Week Range$0.88 – $2.34
Avg Volume1,240,037
ExchangeNASDAQ
Websitecardiolrx.com
Ownership
Float76.2%
Shares Outstanding120.7M
Peers
Recent News
Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC
Nov 3, 2026 · prnewswire.com
Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
Sep 23, 2026 · prnewswire.com
Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
Sep 16, 2026 · prnewswire.com
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
Sep 14, 2026 · zacks.com
Data last updated: Nov 9, 2026, 04:04 AM